BioCentury | Oct 31, 2017
Distillery Therapeutics

Transplant

...INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest RSPO1 and DEFA1 could help prevent GvHD-induced gut dysbiosis...
...after disease induction decreased dysbiosis and intestinal pathology compared with vehicle. Also in the model, DEFA1...
...include testing RSPO1 in other dysbiosis-associated diseases. TARGET/MARKER/PATHWAY: R-Spondin 1 (RSPO1); defensin α 1 (DEFA1; HNP-1...
BioCentury | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 5 (RANTES; CCL5); defensin α 1 (DEFA1; HNP-1)

...disease INDICATION: Inflammation; myocardial infarction (MI) Cell and mouse studies identified a peptide inhibitor of DEFA1...
...cells, a 9-mer peptide derived from the RANTES-binding region of DEFA1 decreased the binding of DEFA1...
...and inflammation. TARGET/MARKER/PATHWAY: Chemokine CC motif ligand 5 (RANTES; CCL5 ); defensin α 1 (DEFA1; HNP-1...
BioCentury | Jun 25, 2015
Distillery Techniques

Techniques: SNPs within defensin α 1 (DEFA1; HNP-1)/defensin β 1 (DEFB1) gene cluster and other loci as risk markers for IgA nephropathy

Biomarkers DEFA1 DEFB1 defensin HNP-1 Sun Yat-sen University BC Staff...
BioCentury | Jan 9, 2014
Distillery Therapeutics

Indication: Infectious disease

...vitro and mouse studies suggest a compound that mimics the antimicrobial peptide defensin a1 (DEFA1; HNP-1...
...In silico, SAR and biological analyses identified low-molecular weight compounds that mimicked the structure of DEFA1...
Items per page:
1 - 4 of 4